/ABT
Abbott Laboratories
ABT • NYSEABT • NYSE • Healthcare
$113.10-0.45%-0.51
$113.10-0.45%(-0.51)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
95Bullish
Risk
90Low Risk
Momentum
29Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
55.5%▲4.7pp
Revenue after COGS
Operating
18.2%▲1.9pp
After operating expenses
Net
14.7%▼17.2pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
33.6
Price vs earnings
EV/EBITDA
19.5
Enterprise value
FCF Yield
3.4%
Cash generation
Earnings Yield
3.0%
Inverse of P/E
Capital Efficiency
9
GoAI Quality ScoreFair
ROEReturn on Equity
12.5%Fair
ROAReturn on Assets
7.5%Strong
ROICReturn on Invested Capital
8.4%Fair
Financial Health
Current RatioHealthy
1.58
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.57x
Debt repayment capacity (<3x)
Income QualityStrong
1.47
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Gross Profit | $24.61B | $21.32B | $20.04B | $22.32B | $23.21B |
| Gross Margin | 55.5% | 50.8% | 50.0% | 51.1% | 53.9% |
| Operating Income | $8.05B | $6.83B | $6.43B | $8.36B | $9.20B |
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| Net Margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% |
| EPS | $3.74 | $7.67 | $3.30 | $3.94 | $3.97 |
Average Price Target
$134.64▲ 19.0% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Abbott Laboratories, the average price target is $134.64, with a high forecast of $152.00 and a low forecast of $120.00. The average price target represents a 19.0% increase from the current price of $113.10.
Highest
$152.00
Average
$134.64
Lowest
$120.00
Rating Distribution
Strong Buy
0
0%
Buy
29
74%
Hold
10
26%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Overweight
2026-02-02BTIG● Maintain
Buy
2026-01-23Citigroup● Maintain
Buy
2026-01-23RBC Capital● Maintain
Outperform
2026-01-23Oppenheimer● Maintain
Outperform
2026-01-23Piper Sandler● Maintain
Overweight
2026-01-23Evercore ISI Group● Maintain
Outperform
2026-01-23Bernstein● Maintain
Outperform
2026-01-23Bernstein● Maintain
Outperform
2026-01-09Barclays● Maintain
Overweight
2026-01-05Earnings History & Surprises
BEAT RATE
72%
Last 18 quarters
AVG SURPRISE
+9.1%
EPS vs Estimate
BEATS / MISSES
13/0
5 met exactly
LATEST EPS
$1.50
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
$1.50 vs $1.50
Q4 '25
$1.30 vs $1.30
Q3 '25
$1.26 vs $1.26
Q2 '25
+1.9%
$1.09 vs $1.07
Q1 '25
$1.34 vs $1.34
Q4 '24
+0.8%
$1.21 vs $1.20
Q3 '24
+3.6%
$1.14 vs $1.10
Q2 '24
+2.6%
$0.98 vs $0.95
Q1 '24
$1.19 vs $1.19
Q4 '23
+3.6%
$1.14 vs $1.10
Q3 '23
+3.8%
$1.08 vs $1.04
Q2 '23
+5.1%
$1.03 vs $0.98
No investor questions available.
Latest News
No news available